Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ninan

Showing results (41-50 of 117) with videos related to

Pageof 12
Sort By:
CNS Spectrums|January 13, 2006
Integrating neurobiology and psychopathology into evidence-based treatment of social anxiety disorderMichael R Liebowitz, Philip T Ninan, Franklin R Schneier, et al.
Clinical Pharmacology and Therapeutics|July 1, 1984
Effect of propranolol on monoamine metabolites in cerebrospinal fluid of patients with chronic schizophreniaM Scheinin, D P van Kammen, P T Ninan, et al.
The Journal of Clinical Psychiatry|April 21, 2004
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatiguePhilip T Ninan, Howard A Hassman, Steven J Glass, et al.
The Primary Care Companion for CNS Disorders|July 7, 2011
Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label studyMichael E Thase, Philip T Ninan, Jeff J Musgnung, et al.
Journal of Pediatric Gastroenterology and Nutrition|October 1, 1992
Atypical genital involvement in a child with Crohn's diseaseT Ninan, P J Aggett, F Smith, et al.
Current Medical Research and Opinion|August 5, 2011
Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and respondersC J Guico-Pabia, Q Jiang, P T Ninan, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2013
BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxinePhilip T Ninan, Richard C Shelton, Weihang Bao, et al.
Journal of Psychiatric Research|September 12, 2012
The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorderSteven J Garlow, Boadie W Dunlop, Philip T Ninan, et al.
Journal of Psychiatric Research|April 6, 2012
Recovery and subsequent recurrence in patients with recurrent major depressive disorderBoadie W Dunlop, Peter Holland, Weihang Bao, et al.
Journal of Clinical Psychopharmacology|April 11, 2014
Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/dArif Khan, Jeff Musgnung, Tanya Ramey, et al.
Pageof 12

Showing results (41-50 of 117) with videos related to

Sort By:
Pageof 12
CNS Spectrums|January 13, 2006
Integrating neurobiology and psychopathology into evidence-based treatment of social anxiety disorderMichael R Liebowitz, Philip T Ninan, Franklin R Schneier, et al.
Clinical Pharmacology and Therapeutics|July 1, 1984
Effect of propranolol on monoamine metabolites in cerebrospinal fluid of patients with chronic schizophreniaM Scheinin, D P van Kammen, P T Ninan, et al.
The Journal of Clinical Psychiatry|April 21, 2004
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatiguePhilip T Ninan, Howard A Hassman, Steven J Glass, et al.
The Primary Care Companion for CNS Disorders|July 7, 2011
Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label studyMichael E Thase, Philip T Ninan, Jeff J Musgnung, et al.
Journal of Pediatric Gastroenterology and Nutrition|October 1, 1992
Atypical genital involvement in a child with Crohn's diseaseT Ninan, P J Aggett, F Smith, et al.
Current Medical Research and Opinion|August 5, 2011
Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and respondersC J Guico-Pabia, Q Jiang, P T Ninan, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2013
BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxinePhilip T Ninan, Richard C Shelton, Weihang Bao, et al.
Journal of Psychiatric Research|September 12, 2012
The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorderSteven J Garlow, Boadie W Dunlop, Philip T Ninan, et al.
Journal of Psychiatric Research|April 6, 2012
Recovery and subsequent recurrence in patients with recurrent major depressive disorderBoadie W Dunlop, Peter Holland, Weihang Bao, et al.
Journal of Clinical Psychopharmacology|April 11, 2014
Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/dArif Khan, Jeff Musgnung, Tanya Ramey, et al.
Pageof 12